(SNDX) Syndax Pharmaceuticals - Ratings and Ratios
Antibody, Kinase, Inhibitor, Oncology, Hematology
SNDX EPS (Earnings per Share)
SNDX Revenue
Description: SNDX Syndax Pharmaceuticals
Syndax Pharmaceuticals Inc (NASDAQ:SNDX) is a US-based biotechnology company. Its stock performance is characterized by a current price of $15.74, indicating a potential rebound from its 52-week low of $8.73. The stocks beta of 0.734 suggests relatively lower volatility compared to the overall market.
The companys market capitalization stands at $1.355 billion, reflecting its size and investor interest. With a negative Return on Equity (RoE) of -130.47, Syndax Pharmaceuticals is currently operating at a loss, which is not uncommon for biotech firms investing heavily in R&D. The absence of a Price-to-Earnings (P/E) ratio further indicates that the company is not yet profitable.
Key economic drivers for Syndax Pharmaceuticals include the progress of its pipeline assets, particularly those in clinical development. The success or failure of its drug candidates can significantly impact its stock performance. Investors should monitor updates on its clinical trials, regulatory approvals, and potential partnerships or collaborations that could influence its financials and stock price.
To evaluate the investment potential of SNDX, one should consider KPIs such as cash burn rate, the timing of key clinical milestones, and the competitive landscape of its therapeutic areas. The companys ability to secure funding, either through equity issuances, debt financing, or partnerships, is also crucial for sustaining its operations and advancing its pipeline.
From a trading perspective, the stocks moving averages (SMA20, SMA50, SMA200) and Average True Range (ATR) can provide insights into its trend and volatility. A trader might look for crossovers between the short-term and long-term moving averages as potential buy or sell signals, while also considering the stocks trading volume to gauge investor interest.
SNDX Stock Overview
| Market Cap in USD | 1,340m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2016-03-03 |
SNDX Stock Ratings
| Growth Rating | -52.8% |
| Fundamental | 27.4% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -31.1% |
| Analyst Rating | 4.67 of 5 |
SNDX Dividends
Currently no dividends paidSNDX Growth Ratios
| Growth Correlation 3m | 90.9% |
| Growth Correlation 12m | -61.6% |
| Growth Correlation 5y | -29.6% |
| CAGR 5y | -14.31% |
| CAGR/Max DD 3y | -0.20 |
| CAGR/Mean DD 3y | -0.46 |
| Sharpe Ratio 12m | 0.16 |
| Alpha | 0.11 |
| Beta | 0.765 |
| Volatility | 57.04% |
| Current Volume | 1492k |
| Average Volume 20d | 1809.3k |
| Stop Loss | 13.7 (-7.1%) |
| Signal | -1.18 |
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income (-335.0m TTM) > 0 and > 6% of Revenue (6% = 4.69m TTM) |
| FCFTA -0.46 (>2.0%) and ΔFCFTA -12.44pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 535.5% (prev 10000 %; Δ -9464 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.51 (>3.0%) and CFO -302.7m > Net Income -335.0m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 4.71 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (86.3m) change vs 12m ago 1.25% (target <= -2.0% for YES) |
| Gross Margin 96.17% (prev -1005 %; Δ 1101 pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 14.57% (prev 0.85%; Δ 13.72pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -13.18 (EBITDA TTM -257.2m / Interest Expense TTM 20.7m) >= 6 (WARN >= 3) |
Altman Z'' -9.65
| (A) 0.70 = (Total Current Assets 531.7m - Total Current Liabilities 113.0m) / Total Assets 596.1m |
| (B) -2.31 = Retained Earnings (Balance) -1.38b / Total Assets 596.1m |
| warn (B) unusual magnitude: -2.31 — check mapping/units |
| (C) -0.51 = EBIT TTM -273.4m / Avg Total Assets 536.5m |
| (D) -3.14 = Book Value of Equity -1.38b / Total Liabilities 438.7m |
| Total Rating: -9.65 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 27.38
| 1. Piotroski 1.50pt = -3.50 |
| 2. FCF Yield -22.97% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 2.07 = 0.67 |
| 5. Debt/Ebitda -1.27 = -2.50 |
| 6. ROIC - WACC (= -87.25)% = -12.50 |
| 7. RoE -130.5% = -2.50 |
| 8. Rev. Trend 90.09% = 6.76 |
| 9. EPS Trend -80.87% = -4.04 |
What is the price of SNDX shares?
Over the past week, the price has changed by -6.23%, over one month by -7.06%, over three months by +53.01% and over the past year by -18.33%.
Is Syndax Pharmaceuticals a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SNDX is around 14.41 USD . This means that SNDX is currently overvalued and has a potential downside of -2.31%.
Is SNDX a buy, sell or hold?
- Strong Buy: 9
- Buy: 2
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the SNDX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 37.5 | 154.2% |
| Analysts Target Price | 37.5 | 154.2% |
| ValueRay Target Price | 15.9 | 7.9% |
Last update: 2025-09-16 04:41
SNDX Fundamental Data Overview
CCE Cash And Equivalents = 468.7m USD (Cash And Short Term Investments, last quarter)
P/S = 17.1879
P/B = 8.5089
Beta = 0.723
Revenue TTM = 78.2m USD
EBIT TTM = -273.4m USD
EBITDA TTM = -257.2m USD
Long Term Debt = 325.7m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 350.0k USD (from shortTermDebt, last quarter)
Debt = 326.1m USD (Calculated: Short Term 350.0k + Long Term 325.7m)
Net Debt = -107.0m USD (from netDebt column, last quarter)
Enterprise Value = 1.20b USD (1.34b + Debt 326.1m - CCE 468.7m)
Interest Coverage Ratio = -13.18 (Ebit TTM -273.4m / Interest Expense TTM 20.7m)
FCF Yield = -22.97% (FCF TTM -274.9m / Enterprise Value 1.20b)
FCF Margin = -351.6% (FCF TTM -274.9m / Revenue TTM 78.2m)
Net Margin = -428.5% (Net Income TTM -335.0m / Revenue TTM 78.2m)
Gross Margin = 96.17% ((Revenue TTM 78.2m - Cost of Revenue TTM 2.99m) / Revenue TTM)
Tobins Q-Ratio = -0.87 (set to none) (Enterprise Value 1.20b / Book Value Of Equity -1.38b)
Interest Expense / Debt = 2.41% (Interest Expense 7.86m / Debt 326.1m)
Taxrate = 21.0% (US default)
NOPAT = -273.4m (EBIT -273.4m, no tax applied on loss)
Current Ratio = 4.71 (Total Current Assets 531.7m / Total Current Liabilities 113.0m)
Debt / Equity = 2.07 (Debt 326.1m / last Quarter total Stockholder Equity 157.4m)
Debt / EBITDA = -1.27 (Net Debt -107.0m / EBITDA -257.2m)
Debt / FCF = -1.19 (Debt 326.1m / FCF TTM -274.9m)
Total Stockholder Equity = 256.8m (last 4 quarters mean)
RoA = -56.19% (Net Income -335.0m, Total Assets 596.1m )
RoE = -130.5% (Net Income TTM -335.0m / Total Stockholder Equity 256.8m)
RoCE = -46.93% (Ebit -273.4m / (Equity 256.8m + L.T.Debt 325.7m))
RoIC = -79.77% (NOPAT -273.4m / Invested Capital 342.7m)
WACC = 7.47% (E(1.34b)/V(1.67b) * Re(8.83%)) + (D(326.1m)/V(1.67b) * Rd(2.41%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 96.97 | Cagr: 3.26%
Discount Rate = 8.83% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -274.9m)
EPS Correlation: -80.87 | EPS CAGR: -17.75% | SUE: 0.50 | # QB: 0
Revenue Correlation: 90.09 | Revenue CAGR: 1300 % | SUE: N/A | # QB: None
Additional Sources for SNDX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle